Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.4049/JIMMUNOL.1401710 | ||||
| Año | 2016 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Treatment of cancer patients by adoptive T cell therapy has yielded promising results. In solid tumors, however, T cells encounter a hostile environment, in particular with increased inflammatory activity as a hallmark of the tumor milieu that goes along with abundant reactive oxygen species (ROS) that substantially impair antitumor activity. We present a strategy to render antitumor T cells more resilient toward ROS by coexpressing catalase along with a tumor specific chimeric Ag receptor (CAR) to increase their antioxidative capacity by metabolizing H2O2. In fact, T cells engineered with a bicistronic vector that concurrently expresses catalase, along with the CAR coexpressing catalase (CAR-CAT), performed superior over CAR T cells as they showed increased levels of intracellular catalase and had a reduced oxidative state with less ROS accumulation in both the basal state and upon activation while maintaining their antitumor activity despite high H2O2 levels. Moreover, CAR-CAT T cells exerted a substantial bystander protection of nontransfected immune effector cells as measured by CD3 zeta chain expression in bystander T cells even in the presence of high H2O2 concentrations. Bystander NK cells, otherwise ROS sensitive, efficiently eliminate their K562 target cells under H2O2-induced oxidative stress when admixed with CAR-CAT T cells. This approach represents a novel means for protecting tumor-infiltrating cells from tumor-associated oxidative stress-mediated repression.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Ligtenberg, Maarten A. | Hombre |
Karolinska Inst - Suecia
Karolinska University Hospital - Suecia Karolinska Institutet - Suecia |
| 2 | Mougiakakos, Dimitrios | Hombre |
UNIV ERLANGEN NURNBERG - Alemania
Friedrich-Alexander-Universität Erlangen-Nürnberg - Alemania |
| 3 | Mukhopadhyay, Madhura | - |
Karolinska Inst - Suecia
Karolinska University Hospital - Suecia Karolinska Institutet - Suecia |
| 4 | Witt, Kristina | Mujer |
Karolinska Inst - Suecia
Karolinska University Hospital - Suecia Karolinska Institutet - Suecia |
| 5 | Lladser, Alvaro | Hombre |
Fundación Ciencia y Vida - Chile
|
| 6 | Chmielewski, Markus | Hombre |
Univ Cologne - Alemania
University of Cologne - Alemania Universität zu Köln - Alemania |
| 7 | Riet, Tobias | Hombre |
Univ Cologne - Alemania
University of Cologne - Alemania Universität zu Köln - Alemania |
| 8 | Abken, Hinrich | Hombre |
Univ Cologne - Alemania
University of Cologne - Alemania Universität zu Köln - Alemania |
| 9 | Kiessling, Rolf | Hombre |
Karolinska Inst - Suecia
Karolinska University Hospital - Suecia Karolinska Institutet - Suecia |
| Fuente |
|---|
| Swedish Medical Research Council |
| Knut and Alice Wallenberg Foundation |
| Else Kroner-Fresenius Stiftung |
| Stockholm City Council Project Grant |
| Deutsche Krebshilfe |
| Swedish Cancer Society Grant |
| Cancer Society of Stockholm Grant |
| Sander-Stiftung |
| Agradecimiento |
|---|
| This work was supported by Swedish Medical Research Council Grant K2011-66X-15387-07-3 VR (to R. K.), Swedish Cancer Society Grant 12 0598 (Cancerfonden), Cancer Society of Stockholm Grant 121103 (Cancerforeningen, Radiumhemmets Forskningsfonder), the Knut and Alice Wallenberg Foundation, and by Stockholm City Council Project Grant 20140036 (ALF Medicine 2015). The H. A. laboratory was supported by the Else Kroner-Fresenius Stiftung, the Sander-Stiftung, and the Deutsche Krebshilfe. |